All In Biotech

Drug Trial Radar · NCT06531707

Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine

Efficacy and Safety of Ibuprofen/Loratadine Fixed-dose Combination Versus the Fixed-dose Administration of Monotherapy as Symptomatic Treatment for Patients With the Common Cold

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 177 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

177

Actual

Start

Jun 24, 2024

Primary completion

Jan 20, 2025

Study completion Sep 12, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the drug combination of Ibuprofen/Loratadine versus Ibuprofen versus Loratadine as monotherapy for the symptomatic treatment of the common cold.

Conditions

  • Common Cold

Interventions

  • Ibuprofen + Loratadine fixed doseDrug

    Suspension 8,000 mg / 100 mg / 100 mL, 5 mL twice a day

  • IbuprofenDrug

    Suspension 2,000 mg / 100 mL, 20 mL twice a day

  • LoratadineDrug

    Suspension 1 mg / 1 mL, 5 mL twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the improvement in symptoms, comparing the percentage change through the Jackson scoreTime frame: 7 days
  2. Number of participants with treatment-related adverse events through the patient's diary record, by treatment groupTime frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Laboratorio Silanes, S.A. de C.V.

    Mexico City, Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.